Please use this identifier to cite or link to this item:
|Title:||Outcomes and safety profile of transperineal prostate biopsy: results from the Victorian Transperineal Biopsy Collaboration.|
|Other Authors:||Huang, Sean|
Ong, Wee Loon
|Keywords:||UroRenal & Vascular Clinical Institute, Epworth HealthCare, Richmond, Victoria, Australia.|
Australian Prostate Cancer Centre Epworth, Richmond, Victoria, Australia.
Cancer of the Prostate
Victorian Transperineal Biopsy Collaboration
|Conference Name:||Fundamentals in Urology|
|Conference Location:||Charlottesville, VA, U.S.|
|Abstract:||Introduction: Transperineal prostate biopsy (TPB) has been proposed as a safer and more sensitive method for obtaining prostate gland biopsy. Herein we review the indications, outcomes and safety profile of TPB utilising our prospective Victorian Transperineal Biopsy Collaboration (VTBC) database. Methods: The VTBC is a multi-institutional registry collecting data prospectively from four contributing institutions across Melbourne, Australia. The database is ethics approved at each institution and data collected is based on the minimum dataset published by the Ginsburg Study Group. Results: The total of 1108 men underwent TPB between June 2010 and June, with 870 having adequate histological data for analysis. The indications for TPB were primary biopsy (43.4%), repeat biopsy in the setting of previous negative TRUS biopsy (18.3%) and confirmatory biopsy for men on active surveillance (35.6%). The mean cohort age was 63.5 (SD 7.8) and median pre-biopsy PSA was 6.5 (IQR 4.7 - 9.7). In 388 men undergoing TPB as initial biopsy, 328/388 (84.5%) were diagnosed with prostate cancer and 215/388 (55.4%) were diagnosed with Gleason ? 7 disease. In 164 men with a prior negative TRUS biopsy, 51/164 (31.1%) were found to have prostate cancer and 35/164 (21.3%) were diagnosed with Gleason ? 7 disease. Of 318 patients on active surveillance, 137/318 (43%) were upstaged to Gleason ? 7 disease. Overall 230 (25.7%) men were diagnosed with an anterior tumour. The overall rate of acute urinary retention was 3.2%. Only 3(0.3%) patients in the cohort required hospital admission due to biopsy related infection. Conclusions: The VTBC is the largest reported database of patients having TPB in Australia and New Zealand. The current results show that TPB is a safe procedure with minimal complications. TPB may prove an effective modality for diagnosing significant prostate cancers often missed by traditional biopsy methods. The performance of TPB compared to MRI guided fusion biopsy in various biopsy settings and the potential impact of TPB on erectile function need further investigation.|
|Type of Clinical Study or Trial:||Prospective Cohort Study|
|Appears in Collections:||Cancer Services|
Epworth Prostate Centre
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.